Part 3.2 / M13, M15

Index No

►M18  Chemical name ◄

EC No

CAS No

Classification

Labelling

►M18  Specific Conc. Limits, M-factors and ATEs (*1)  ◄

Notes

Hazard Class and

Category Code(s)

Hazard statement Code(s)

Pictogram, Signal Word Code(s)

Hazard statement Code(s)

Suppl. Hazard statement Code(s)

▼M16

005-020-00-3

disodium octaborate anhydrous; [1]

disodium octaborate tetrahydrate [2]

234-541-0 [1]

234-541-0 [2]

12008-41-2 [1]

12280-03-4 [2]

Repr. 1B

H360FD

GHS08

Dgr

H360FD

006-035-00-8

pirimicarb (ISO); 2-(dimethylamino)-5,6-dimethylpyrimidin-4-yl dimethylcarbamate

245-430-1

23103-98-2

Carc. 2

Acute Tox. 3

Acute Tox. 3

Skin Sens. 1

Aquatic Acute 1 Aquatic Chronic 1

H351

H331

H301

H317

H400

H410

GHS08

GHS06

GHS09

Dgr

H351

H331

H301

H317

H410

M = 10

M = 100

006-046-00-8

bendiocarb (ISO);

2,2-dimethyl-1,3-benzodioxol-4-yl N-methylcarbamate;

2,2-dimethyl-1,3-benzodioxol-4-yl methylcarbamate

245-216-8

22781-23-3

Acute Tox. 3

Acute Tox. 3

Acute Tox. 2

Aquatic Acute 1

Aquatic Chronic 1

H331

H311

H300

H400

H410

GHS06

GHS09

Dgr

H331

H311

H300

H410

M = 10

M = 100

014-046-00-4

e-glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following representative composition (% given by weight): SiO2 50,0-56,0 %, Al2O3 13,0-16,0 %, B2O3 5,8-10,0 %, Na2O < 0,6 %, K2O < 0,4 %, CaO 15,0-24,0 %, MgO < 5,5 %, Fe2O3 < 0,5 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additionalindividual elements may be present at low levels; the process list does not preclude innovation).]

—

—

Carc. 1B

H350i

GHS08

Dgr

H350i

A

014-047-00-X

glass microfibres of representative composition; [Calcium-aluminium-silicate fibres with random orientation with the following composition (% given by weight): SiO2 55,0-60,0 %, Al2O3 4,0-7,0 %, B2O3 8,0-11,0 %, ZrO2 0,0-4,0 %, Na2O 9,5-13,5 %, K2O 0,0-4,0 %, CaO 1,0-5,0 %, MgO 0,0-2,0 %, Fe2O3 < 0,2 %, ZnO 2,0-5,0 %, BaO 3,0-6,0 %, F2 < 1,0 %. Process: typically produced by flame attenuation and rotary process. (Additional individual elements may be present at low levels; the process list does not preclude innovation).]

—

—

Carc. 2

H351 (inhalation)

GHS08

Wng

H351 (inhalation)

A

047-003-00-3

silver zinc zeolite (Zeolite, LTA framework type, surface-modified with silver and zinc ions)

[This entry covers LTA (Linde Type A) framework type zeolite which has been surface-modified with both silver and zinc ions at contents Ag+ 0,5 %-6 %, Zn2 + 5 %-16 %, and potentially with phosphorus, NH4+, Mg2+ and/or Ca2+ each at level < 3 %]

—

130328-20-0

Repr. 2

Skin Irrit. 2

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H361d

H315

H318

H400

H410

GHS08

GHS05

GHS09

Dgr

H361d

H315

H318

H410

M = 100

M = 100

048-012-00-5

cadmium carbonate

208-168-9

513-78-0

Carc. 1B

Muta. 1B

Acute Tox. 4 *

Acute Tox. 4 *

Acute Tox. 4 *

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H350

H340

H332

H312

H302

H372 (kidney, bone)

H400

H410

GHS08

GHS07

GHS09

Dgr

H350

H340

H332

H312

H302

H372 (kidney, bone)

H410

A1

048-013-00-0

cadmium hydroxide; cadmium dihydroxide

244-168-5

21041-95-2

Carc. 1B

Muta. 1B

Acute Tox. 4 *

Acute Tox. 4 *

Acute Tox. 4 *

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H350

H340

H332

H312

H302

H372 (kidney, bone)

H400

H410

GHS08

GHS07

GHS09

Dgr

H350

H340

H332

H312

H302

H372 (kidney, bone)

H410

A1

048-014-00-6

cadmium nitrate;

cadmium dinitrate

233-710-6

10325-94-7

Carc. 1B

Muta. 1B

Acute Tox. 4 *

Acute Tox. 4 *

Acute Tox. 4 *

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H350

H340

H332

H312

H302

H372 (kidney, bone)

H400

H410

GHS08

GHS07

GHS09

Dgr

H350

H340

H332

H312

H302

H372 (kidney, bone)

H410

Carc. 1B; H350:

C ≥ 0,01 %

A1

050-030-00-3

dibutyltin dilaurate; dibutyl[bis(dodecanoyloxy)]stannane

201-039-8

77-58-7

Muta. 2

Repr. 1B

STOT RE 1

H341

H360FD

H372 (immune system)

GHS08

Dgr

H341

H360FD

H372 (immune system)

602-020-00-0

1,2-dichloropropane;

propylene dichloride

201-152-2

78-87-5

Flam. Liq. 2

Carc. 1B

Acute Tox. 4*

Acute Tox. 4*

H225

H350

H332

H302

GHS02

GHS08

GHS07

Dgr

H225

H350

H332

H302

602-033-00-1

chlorobenzene

203-628-5

108-90-7

Flam. Liq. 3

Acute Tox. 4

Skin Irrit. 2

Aquatic Chronic 2

H226

H332

H315

H411

GHS02

GHS07

GHS09

Wng

H226

H332

H315

H411

603-055-00-4

propylene oxide;

1,2-epoxypropane; methyloxirane

200-879-2

75-56-9

Flam. Liq. 1

Carc. 1B

Muta. 1B

Acute Tox. 3

Acute Tox. 3

Acute Tox. 4

STOT SE 3

Eye Irrit. 2

H224

H350

H340

H331

H311

H302

H335

H319

GHS02

GHS08

GHS06

Dgr

H224

H350

H340

H331

H311

H302

H335

H319

603-235-00-2

linalool; 3,7-dimethyl-1,6-octadien-3-ol; dl-linalool; [1]

coriandrol; (S)-3,7-dimethyl-1,6-octadien-3-ol; d-linalool; [2]

licareol; (R)-3,7-dimethyl-1,6-octadien-3-ol; l-linalool [3]

201-134-4 [1]

204-810-7 [2]

204-811-2 [3]

78-70-6 [1]

126-90-9 [2]

126-91-0 [3]

Skin Sens. 1B

H317

GHS07

Wng

H317

604-057-00-8

reaction mass of: isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-dodecylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-(n)-tetracosylphenol; isomers of 2-(2H-benzotriazol-2-yl)-4-methyl-5,6-didodecyl-phenol. n = 5 or 6

401-680-5

—

Aquatic Chronic 4

H413

H413

604-092-00-9

phenol, dodecyl-, branched; [1]

phenol, 2-dodecyl-, branched; [2]

phenol, 3-dodecyl-, branched; [3]

phenol, 4-dodecyl-, branched; [4]

phenol, (tetrapropenyl) derivatives [5]

310-154-3 [1]

[2]

[3]

[4]

[5]

121158-58-5 [1]

[2]

[3]

210555-94-5 [4]

74499-35-7 [5]

Repr. 1B

Skin Corr. 1C

Eye Dam. 1

Aquatic Acute 1 Aquatic Chronic 1

H360F

H314

H318

H400

H410

GHS08

GHS05

GHS09

Dgr

H360F

H314

H410

M = 10

M = 10

604-093-00-4

clorofene;

chlorophene;

2-benzyl-4-chlorophenol

204-385-8

120-32-1

Carc. 2

Repr. 2

Acute Tox. 4

Skin Irrit. 2

Skin Sens. 1

Eye Dam. 1

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H361f

H332

H315

H317

H318

H373 (kidney)

H400

H410

GHS08

GHS05

GHS07

GHS09

Dgr

H351

H361f

H332

H315

H317

H318

H373 (kidney)

H410

M = 1

M = 100

605-013-00-0

chloralose (INN);

(R)-1,2-O-(2,2,2-trichloroethylidene)-α-D-glucofuranose; glucochloralose; anhydroglucochloral

240-016-7

15879-93-3

Acute Tox. 4*

Acute Tox. 3

STOT SE 3

Aquatic Acute 1

Aquatic Chronic 1

H332

H301

H336

H400

H410

GHS06

GHS09

Dgr

H332

H301

H336

H410

M = 10

M = 10

C

605-022-00-X

glutaral; glutaraldehyde;

1,5-pentanedial

203-856-5

111-30-8

Acute Tox. 2

Acute Tox. 3

STOT SE 3

Skin Corr. 1B

Resp. Sens. 1

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 2

H330

H301

H335

H314

H334

H317

H400

H411

GHS06

GHS05

GHS08

GHS09

Dgr

H330

H301

H335

H314

H334

H317

H410

EUH071

STOT SE 3; H335: 0,5 % ≤ C < 5 %

M = 1

605-023-00-5

5-chloro-2-(4-chlorophenoxy)phenol;

[DCPP]

429-290-0

3380-30-1

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H318

H400

H410

GHS05

GHS09

Dgr

H318

H410

M = 10

M = 10

605-040-00-8

hydroxyisohexyl 3-cyclohexene carboxaldehyde (INCI); reaction mass of 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [1]

4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; [2]

3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde [3]

- [1]

250-863-4 [2]

257-187-9 [3]

130066-44-3 [1]

31906-04-4 [2]

51414-25-6 [3]

Skin Sens. 1A

H317

GHS07

Wng

H317

606-014-00-9

chlorophacinone (ISO);

2-[(4-chlorophenyl)(phenyl)acetyl]-1H-indene-1,3(2H)-dione

223-003-0

3691-35-8

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,1 %

STOT RE 2; H373 (blood):

0,01 % ≤ C < 0,1 %

M = 1

M = 1

606-021-00-7

N-methyl-2-pyrrolidone; 1-methyl-2-pyrrolidone

212-828-1

872-50-4

Repr. 1B

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

H360D***

H335

H315

H319

GHS08

GHS07

Dgr

H360D***

H335

H315

H319

STOT SE 3; H335: C ≥ 10 %

606-041-00-6

2-methyl-1-(4-methylthiophenyl)-2-morpholinopropan-1-one

400-600-6

71868-10-5

Repr. 1B

Acute Tox. 4 *

Aquatic Chronic 2

H360FD

H302

H411

GHS08

GHS07

GHS09

Dgr

H360FD

H302

H411

606-150-00-9

clethodim (ISO); (5RS)-2-{(1EZ)-1-[(2E)-3-chloroallyloxyimino]propyl}-5-[(2RS)-2-(ethylthio)propyl]-3-hydroxycyclohex-2-en-1-one

—

99129-21-2

Acute Tox. 4

Skin Sens. 1

Aquatic Chronic 3

H302

H317

H412

GHS07

Wng

H302

H317

H412

EUH066

606-151-00-4

anthraquinone

201-549-0

84-65-1

Carc. 1B

H350

GHS08

Dgr

H350

607-056-00-0

warfarin (ISO);

4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one; [1]

(S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone; [2]

(R)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone [3]

201-377-6

[1]

226-907-3

[2]

226-908-9

[3]

81-81-2 [1]

5543-57-7

[2]

5543-58-8

[3]

Repr. 1A

Acute Tox. 1

Acute Tox. 1

Acute Tox. 2

STOT RE 1

Aquatic Chronic 2

H360D

H330

H310

H300

H372 (blood)

H411

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H411

Repr. 1A; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,5 %

STOT RE 2; H373 (blood): 0,05 % ≤ C < 0,5 %

607-059-00-7

coumatetralyl (ISO); 4-hydroxy-3-(1,2,3,4-tetrahydro-1-naphthyl)coumarin

227-424-0

5836-29-3

Repr. 1B

Acute Tox. 2

Acute Tox. 3

Acute Tox. 2

STOT RE 1

Aquatic Chronic 1

H360D

H330

H311

H300

H372 (blood)

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H311

H300

H372 (blood)

H410

Repr. 1B; H360D: C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 1,0 %

STOT RE 2; H373 (blood) 0,1 % ≤ C < 1,0 %

M = 10

607-123-00-4

2,3-epoxypropyl methacrylate;

glycidyl methacrylate

203-441-9

106-91-2

Carc. 1B

Muta. 2

Repr. 1B

Acute Tox. 3

Acute Tox. 4

STOT SE 3

STOT RE 1

Eye Dam. 1

Skin Corr. 1C

Skin Sens. 1

H350

H341

H360F

H311

H302

H335

H372 (respiratory tract) (inhalation)

H318

H314

H317

GHS08

GHS06

GHS05

Dgr

H350

H341

H360F

H311

H302

H335

H372 (respiratory tract) (inhalation)

H314

H317

D

607-157-00-X

difenacoum (ISO); 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin

259-978-4

56073-07-5

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):

0,002 % ≤ C < 0,02 %

M = 10

M = 10

607-172-00-1

brodifacoum (ISO);

4-hydroxy-3-(3-(4′-bromo-4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)coumarin

259-980-5

56073-10-0

Repr. 1A

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1A; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):

0,002 % ≤ C < 0,02 %

M = 10

M = 10

607-375-00-5

flocoumafen (ISO); reaction mass of: cis-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin and trans-4-hydroxy-3-(1,2,3,4-tetrahydro-3-(4-(4-trifluoromethylbenzyloxy)phenyl)-1-naphthyl)coumarin

421-960-0

90035-08-8

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,05 %

STOT RE 2; H373 (blood):

0,005 % ≤ C < 0,05 %

M = 10

M = 10

607-623-00-2

diisobutyl phthalate

201-553-2

84-69-5

Repr. 1B

H360Df

GHS08

Dgr

H360Df

607-716-00-8

bromadiolone (ISO); 3-[3-(4′-bromobiphenyl-4-yl)-3-hydroxy-1-phenylpropyl]-4-hydroxy-2H-chromen-2-one

249-205-9

28772-56-7

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,005 % STOT RE 2; H373 (blood):

0,0005 % ≤ C < 0,005 %

M = 1

M = 1

607-717-00-3

difethialone (ISO);

3-[3-(4′-bromobiphenyl-4-yl)-1,2,3,4-tetrahydronaphthalen-1-yl]-4-hydroxy-2H-1-benzothiopyran-2-one

—

104653-34-1

Repr. 1B

Acute Tox. 1

Acute Tox. 1

Acute Tox. 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H330

H310

H300

H372 (blood)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H330

H310

H300

H372 (blood)

H410

EUH070

Repr. 1B; H360D:

C ≥ 0,003 %

STOT RE 1; H372 (blood): C ≥ 0,02 % STOT RE 2; H373 (blood):

0,002 % ≤ C < 0,02 %

M = 100

M = 100

607-718-00-9

perfluorononan-1-oic acid [1] and its sodium [2] and ammonium [3] salts

206-801-3 [1]

[2]

[3]

375-95-1 [1]

21049-39-8 [2]

4149-60-4 [3]

Carc. 2

Repr. 1B

Lact.

Acute Tox. 4

Acute Tox. 4

STOT RE 1

Eye Dam. 1

H351

H360Df

H362

H332

H302

H372 (liver, thymus, spleen)

H318

GSH08

GSH07

GHS05

Dgr

H351

H360Df

H362

H332

H302

H372 (liver, thymus, spleen)

H318

607-719-00-4

dicyclohexyl phthalate

201-545-9

84-61-7

Repr. 1B

Skin Sens. 1

H360D

H317

GHS08

GHS07

Dgr

H360D

H317

607-720-00-X

nonadecafluorodecanoic acid; [1]

ammonium nonadecafluorodecanoate; [2]

sodium nonadecafluorodecanoate [3]

206-400-3 [1] 221-470-5 [2]

[3]

335-76-2 [1] 3108-42-7 [2]

3830-45-3 [3]

Carc. 2

Repr. 1B

Lact.

H351

H360Df

H362

GHS08

Dgr

H351

H360Df

H362

607-721-00-5

N,N′-methylenedimorpholine;

N,N′-methylenebismorpholine;

[formaldehyde released from N,N′-methylenebismorpholine];

[MBM]

227-062-3

5625-90-1

Carc. 1B

Muta. 2

Acute Tox. 4

Acute Tox. 4

Acute Tox. 4

STOT RE 2

Skin Corr. 1B

Skin Sens. 1

Eye Dam. 1

H350

H341

H332

H312

H302

H373 (gastrointestinal tract, respiratory tract)

H314

H317

H318

GHS08

GHS07

GHS05

Dgr

H350

H341

H332

H312

H302

H373 (gastrointestinal tract, respiratory tract)

H314

H317

EUH071

8

9

607-722-00-0

2,3,5,6-tetrafluoro-4-(methoxymethyl)benzyl (Z)-(1R,3R)-3-(2-cyanoprop-1-enyl)-2,2-dimethylcyclopropanecarboxylate;

epsilon-momfluorothrin

—

1065124-65-3

Acute Tox. 4

STOT SE 2

Aquatic Acute 1

Aquatic Chronic 1

H302

H371 (nervous system)

H400

H410

GHS07

GHS08

GHS09

Wng

H302

H371 (nervous system)

H410

M = 100

M = 100

607-723-00-6

tefluthrin (ISO);

2,3,5,6-tetrafluoro-4-methylbenzyl (1RS,3RS)-3-[(Z)-2-chloro-3,3,3-trifluoroprop-1-enyl]-2,2-dimethylcyclopropanecarboxylate

—

79538-32-2

Acute Tox. 1

Acute Tox. 2

Acute Tox. 2

Aquatic Acute 1

Aquatic Chronic 1

H330

H310

H300

H400

H410

GHS06

GHS09

Dgr

H330

H310

H300

H410

M = 10 000

M = 10 000

608-055-00-8

fipronil (ISO);

(±)-5-amino-1-(2,6-dichloro-α,α,α-trifluoro-para-tolyl)-4-trifluoromethylsulfinyl-pyrazole-3-carbonitrile

424-610-5

120068-37-3

Acute Tox. 3*

Acute Tox. 3*

Acute Tox. 3*

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H301

H311

H331

H372*

H400

H410

GHS06

GHS08

GHS09

Dgr

H301

H311

H331

H372*

H410

M = 1 000

M = 10 000

608-067-00-3

3,7-dimethylocta-2,6-dienenitrile

225-918-0

5146-66-7

Muta. 1B

H340

GHS08

Dgr

H340

612-150-00-X

spiroxamine (ISO);

8-tert-butyl-1,4-dioxaspiro[4.5]decan-2-ylmethyl(ethyl)(propyl)amine

—

118134-30-8

Repr. 2

Acute Tox. 4

Acute Tox. 4

Acute Tox. 4

STOT RE 2

Skin Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H361d

H332

H312

H302

H373 (eye)

H315

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H361d

H332

H312

H302

H373 (eye)

H315

H317

H410

M = 100

M = 100

612-288-00-0

bupirimate (ISO);

5-butyl-2-ethylamino-6-methylpyrimidin-4-yl dimethylsulphamate

255-391-2

41483-43-6

Carc. 2

Skin Sens. 1B

Aquatic Chronic 1

H351

H317

H410

GHS08

GHS07

GHS09

Wng

H351

H317

H410

M = 1

612-289-00-6

triflumizole (ISO);

(1E)-N-[4-chloro-2-(trifluoromethyl)phenyl]-1-(1H-imidazol-1-yl)-2-propoxyethanimine

—

68694-11-1

Repr. 1B

Acute Tox. 4

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H302

H373 (liver)

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H360D

H302

H373 (liver)

H317

H410

M = 1

M = 1

612-290-00-1

reaction products of paraformaldehyde and 2-hydroxypropylamine (ratio 3:2);

[formaldehyde released from 3,3′-methylenebis[5-methyloxazolidine];

formaldehyde released from oxazolidin];

[MBO]

—

—

Carc. 1B

Muta. 2

Acute Tox. 4

Acute Tox. 3

Acute Tox. 4

STOT RE 2

Skin Corr. 1B

Eye Dam. 1

Skin Sens. 1A

Aquatic Chronic 2

H350

H341

H332

H311

H302

H373 (gastrointestinal tract, respiratory tract)

H314

H318

H317

H411

GHS08

GHS06

GHS05

GHS09

Dgr

H350

H341

H332

H311

H302

H373 (gastrointestinal tract, respiratory tract)

H314

H317

H411

EUH071

8

9

612-291-00-7

reaction products of paraformaldehyde with 2-hydroxypropylamine (ratio 1:1);

[formaldehyde released from α,α,α-trimethyl-1,3,5-triazine-1,3,5(2H,4H,6H)-triethanol];

[HPT]

—

—

Carc. 1B

Muta. 2

Acute Tox. 4

Acute Tox. 4

STOT RE 2

Skin Corr. 1C

Eye Dam. 1

Skin Sens. 1A

Aquatic Chronic 2

H350

H341

H332

H302

H373 (gastrointestinal tract, respiratory tract)

H314

H318

H317

H411

GHS08

GHS07

GHS05

GHS09

Dgr

H350

H341

H332

H302

H373 (gastrointestinal tract, respiratory tract)

H314

H317

H411

EUH071

8

9

612-292-00-2

methylhydrazine

200-471-4

60-34-4

Carc. 1B

H350

GHS08

Dgr

H350

613-121-00-4

chlorsulfuron (ISO); 2-chloro-N-[[(4-methoxy-6-methyl-1,3,5-triazin-2- yl)amino]carbonyl]benzenesulphonamide

265-268-5

64902-72-3

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1 000

M = 100

613-318-00-5

fenpyrazamine (ISO);

S-allyl 5-amino-2,3-dihydro-2-isopropyl-3-oxo-4-(o-tolyl)pyrazole-1-carbothioate;

S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydropyrazole-1-carbothioate

—

473798-59-3

Aquatic Acute 1 Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 10

M = 1

613-321-00-1

(RS)-4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole;

medetomidine

—

86347-14-0

Acute Tox. 2

Acute Tox. 2

STOT SE 3

STOT SE 1

STOT RE 1

Aquatic Acute 1

Aquatic Chronic 1

H330

H300

H336

H370 (eye)

H372

H400

H410

GHS06

GHS08

GHS09

Dgr

H330

H300

H336

H370 (eye)

H372

H410

M = 1

M = 100

613-322-00-7

triadimenol (ISO); (1RS,2RS;1RS,2SR)-1-(4-chlorophenoxy)-3,3-dimethyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol;

α-tert-butyl-β-(4-chlorophenoxy)-1H-1,2,4-triazole-1-ethanol

259-537-6

55219-65-3

Repr. 1B

Lact.

Acute Tox. 4

Aquatic Chronic 2

H360

H362

H302

H411

GHS08

GHS07

GHS09

Dgr

H360

H362

H302

H411

613-323-00-2

terbuthylazine (ISO);

N-tert-butyl-6-chloro-N′-ethyl-1,3,5-triazine-2,4-diamine

227-637-9

5915-41-3

Acute Tox. 4

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H302

H373

H400

H410

GHS07

GHS08

GHS09

Wng

H302

H373

H410

M = 10

M = 10

613-324-00-8

quinolin-8-ol;

8-hydroxyquinoline

205-711-1

148-24-3

Repr. 1B

Acute Tox. 3

Eye Dam. 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H360D

H301

H318

H317

H400

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H360D

H301

H318

H317

H410

M = 1

M = 1

613-325-00-3

thiacloprid (ISO);

(Z)-3-(6-chloro-3-pyridylmethyl)-1,3-thiazolidin-2-ylidenecyanamide;

{(2Z)-3-[(6-chloropyridin-3-yl)methyl]-1,3-thiazolidin-2-ylidene}cyanamide

—

111988-49-9

Carc. 2

Repr. 1B

Acute Tox. 4

Acute Tox. 3

STOT SE 3

Aquatic Acute 1

Aquatic Chronic 1

H351

H360FD

H332

H301

H336

H400

H410

GHS08 GHS06

GHS09

Dgr

H351

H360FD

H332

H301

H336

H410

M = 100

M = 100

615-013-00-2

cyanamide;

carbamonitril

206-992-3

420-04-2

Carc. 2

Repr. 2

Acute Tox. 3

Acute Tox. 3

STOT RE 2

Skin Corr. 1

Skin Sens. 1

Eye Dam. 1

Aquatic Chronic 3

H351

H361fd

H311

H301

H373 (thyroid)

H314

H317

H318

H412

GHS08

GHS06

GHS05

Dgr

H351

H361fd

H311

H301

H373 (thyroid)

H314

H317

H412

616-006-00-7

dichlofluanid (ISO);

N-[(dichlorofluoromethyl)thio]-N′,N′-dimethyl-N-phenylsulfamide

214-118-7

1085-98-9

Acute Tox. 4

Eye Irrit. 2

Skin Sens. 1

Aquatic Acute 1

H332

H319

H317

H400

GHS07

GHS09

Wng

H332

H319

H317

H400

M = 10

616-011-00-4

N,N-dimethylacetamide

204-826-4

127-19-5

Repr. 1B

Acute Tox. 4*

Acute Tox. 4*

H360D***

H332

H312

GHS08

GHS07

Dgr

H360D***

H332

H312

616-037-00-6

acetochlor (ISO); 2-chloro-N-(ethoxymethyl)-N-(2-ethyl-6-methylphenyl)acetamide

251-899-3

34256-82-1

Carc. 2

Repr. 2

Acute Tox. 4

STOT SE 3

STOT RE 2

Skin Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H361f

H332

H335

H373 (kidney)

H315

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361f

H332

H335

H373 (kidney)

H315

H317

H410

M = 1 000

M = 100

616-094-00-7

3,3′-dicyclohexyl-1,1′-methylenebis(4,1-phenylene)diurea

406-370-3

58890-25-8

Aquatic Chronic 4

H413

H413

616-207-00-X

polyhexamethylene biguanide hydrochloride;

PHMB

—

32289-58-0

27083-27-8

Carc. 2

Acute Tox. 2

Acute Tox. 4

STOT RE 1

Eye Dam. 1

Skin Sens. 1B

Aquatic Acute 1

Aquatic Chronic 1

H351

H330

H302

H372 (respiratory tract) (inhalation)

H318

H317

H400

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H351

H330

H302

H372 (respiratory tract) (inhalation)

H318

H317

H410

M = 10

M = 10

616-218-00-X

benzovindiflupyr (ISO); N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide

—

1072957-71-1

Acute Tox. 3

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H331

H301

H400

H410

GHS06

GHS09

Dgr

H331

H301

H410

M = 100

M = 100

616-219-00-5

fluopyram (ISO); N-{2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethyl}-2-(trifluoromethyl)benzamide

—

658066-35-4

Aquatic Chronic 2

H411

GHS09

H411

616-220-00-0

pencycuron (ISO); 1-[(4-chlorophenyl)methyl]-1-cyclopentyl-3-phenylurea

266-096-3

66063-05-6

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1

M = 1

616-221-00-6

hexaflumuron (ISO);

1-(3,5-dichloro-4-(1,1,2,2-tetrafluoroethoxy)phenyl)-3-(2,6-difluorobenzoyl)urea

401-400-1

86479-06-3

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1 000

M = 10 000

616-222-00-1

penthiopyrad (ISO);

(RS)-N-[2-(1,3-dimethylbutyl)-3-thienyl]-1-methyl-3-(trifluoromethyl)pyrazole-4-carboxamide

—

183675-82-3

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410

M = 1

M = 1

616-223-00-7

carbetamide (ISO);

(R)-1-(ethylcarbamoyl)ethyl carbanilate; (2R)-1-(ethylamino)-1-oxopropan-2-yl phenylcarbamate

240-286-6

16118-49-3

Carc. 2

Repr. 1B

Acute Tox. 4

Aquatic Chronic 2

H351

H360D

H302

H411

GHS08

GHS07

GHS09

Dgr

H351

H360D

H302

H411

617-023-00-2

tert-butyl hydroperoxide

200-915-7

75-91-2

Muta. 2

H341

GHS08

Wng

H341

650-032-00-X

cyproconazole (ISO); (2RS,3RS;2RS,3SR)-2-(4-chlorophenyl)-3-cyclopropyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol

—

94361-06-5

Repr. 1B

Acute Tox. 3

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H360D

H301

H373 (liver)

H400

H410

GHS08

GHS06

GHS09

Dgr

H360D

H301

H373 (liver)

H410

M = 10

M = 1